Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...

Coinfection with RSV, REV, and MPV was significantly associated with treatment failure and prolonged treatment in children with viral LRTIs on respiratory support.

RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people can recover within a week or two, the virus can cause severe illness in certain groups, ...

This year’s World Health Day centres around improving maternal and newborn health, and kickstarts a year-long campaign from ...

A new antibody shot could help infants who contract respiratory ... significant lasting difference in what RSV, how it impacts our community." The treatment is also recommended for older adults ...

Most treatments are supportive ... RSV disease Pregnant women during weeks 32-36 of pregnancy Infants can be protected from RSV early in life with an RSV antibody given soon after they're born.

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

“ArkBio is dedicated to drug development for RSV treatment that is represented ... posing a significant threat to children under five years. It also increases the risk of asthma and recurrent ...